BSL operates a state-of-the-art, cGMP-compliant manufacturing facility in Vadodara, Gujarat, specializing in Carbapenem APIs and finished-dose injectables.
As one of India’s largest manufacturing facilities dedicated to Carbapenem injections, our vertically integrated capabilities enable greater control across the value chain—from API to finished formulation—supporting consistent quality, reliable supply, and faster access to global markets.
A state of the art R&D facility for API & Injectable formulation development, providing an integrated ecosystem from molecule conceptualization to scale-up readiness, backed by an advanced analytical lab.
Our facility is approved by leading regulatory authorities across the US, Europe, UK, Canada, Brazil, South Africa, Colombia, and other international markets, with 75+ marketing authorizations globally. With deep expertise in Carbapenem anti-infectives and a portfolio of soon to be, vertically integrated formulations. BSL is built to deliver quality, scale, and regulatory confidence to partners worldwide.
BSL Limited is founded by first-generation entrepreneurs Mr. Atul Ranchal and Mr. Rajesh Mahajan, built on the conviction that world-class pharmaceutical manufacturing and affordable access are not competing goals. The company started with a focused formulations mandate that later defined its specialisation in sterile injectable manufacturing.
A significant step forward came in 2006 with the establishment of the Baddi manufacturing facility receiving WHO-GMP approval strengthened BLL manufacturing foundation and demonstrated its focus on maintaining globally recognized standards of pharmaceutical quality.
To enter the market of niche products BSL acquired 66066 Square Meter Land for installing a state of Art dedicated carbapenem facility for Regulated Markets in State of Gujarat near Vadodara City with clean environment.
BLL commenced its commercial production at its Vadodara site in state of Gujarat India in March 2017 for niche products. Receiving EU-GMP approval further strengthened the foundation of Qualitative products with its commitment of providing safe and quality products to the patients.
Quality remained at the heart of BSL progress, with WHO-GMP certification achieved in 2018. The milestone reinforced its manufacturing standards and strengthened the company’s capabilities to meet evolving requirements across domestic and international pharmaceutical markets.
The year 2019 marked broader international recognition, as BLL secured accreditations in Ivory Coast, Cambodia, and Nigeria through NAFDAC. These achievements opened opportunities across new markets while reinforcing the company’s commitment to regulatory and quality requirements.
Brooks achieved another milestone by partnering with Steriscience Specialities Private Limited in March 2021 to further strengthen the Quality know-how and reach the regulated markets like United States and European Markets. The facility was renamed as Brooks Steriscience Limited from April 2021
In 2021, BSL marked a significant milestone with the creation of its manufacturing capabilities, followed by USFDA, ANVISA Brazil approval and the commencement of supplies to regulated international markets.
By 2024, BSL had further strengthened its international presence, achieving accreditations in Syria, Vietnam, and the Democratic Republic of Congo. These milestones represent its ongoing journey toward expanding global access to quality pharmaceutical products and building stronger international partnerships.
First company to get USFDA approval for 2g meropenem under generic product.
With a newly inaugurated API facility enabling in-house vertical integration, BSL continues to scale capacity — delivering from API to finished dose, from India to the world.
Ankit Gupta
Chief Executive Officer
Ankit Gupta is the Chief Executive Officer of Brooks, with over 16 years of experience in finance, corporate strategy, and business transformation across the pharmaceutical and biotechnology sectors. He brings deep expertise in driving growth, strategic planning, corporate development, and operational excellence.
Prior to joining Steriscience, Ankit served as Vice President – Strategy and Corporate Development, where he played a key role in shaping long-term strategy and delivering a successful business turnaround.
A gold medalist in MBA (Finance), Ankit holds globally recognized certifications in corporate finance, private equity, valuation, business leadership and strategy. In addition to leading Steriscience, he also oversees the Group’s B2B businesses.
Swamy K N
Chief Technical Officer
Swamy K N is the Chief Technical Officer at BSL, with over 25 years of experience leading R&D, Operations, and Quality across the pharmaceutical industry. He has extensive expertise in the development and commercialization of complex generics, injectables, and specialty products, driving innovation from concept to market.
Known for building high-performing teams and championing Quality by Design (QbD), Swamy combines scientific excellence with operational rigor to accelerate product development, strengthen regulatory compliance, and enhance manufacturing efficiency across global markets.
Swati Kumari
VP, Global Business Development
Vice President and Global Business Development Head at BSL, a global pharmaceutical company focused on value-added injectable products. She will lead global commercial strategy, drive growth, and strengthen our B2B business across regulated and emerging markets.
Swati brings extensive experience in pharmaceutical business development, portfolio strategy, and P&L management, Licensing with prior leadership roles at Strides Pharma. She has also worked with Cipla and Dr. Reddy’s Laboratories, gaining exposure to global markets.
With a proven track record in partnerships and market expansion, Swati will play a key role in advancing Steriscience’s growth. We look forward to her leadership as we continue to strengthen our global presence.
Sangeetha K
VP & Head , Group Regulatory Affairs
Sangeetha leads Group Regulatory Affairs, shaping regulatory strategy across pipeline prioritization, business development, product development, and lifecycle management.
With over 20 years of experience, she specializes in ready-to-use (RTU) formats and complex injectables, driving global regulatory intelligence, compliance, and market approvals. She has secured approvals across the US, EU, UK, Australia, and Canada, and plays a key role in accelerating product launches and supporting Steriscience's sterile injectable business through strategic regulatory leadership.
Santosh Khare
Director, Site
Mr. Santosh Khare serves as Vice President (Projects and Operations) and Plant Head at BSL, Vadodara overseeing plant management, technology transfer, and operational strategy.
With over two decades of experience in sterile injectable and API manufacturing across sterile and non-sterile segments, he brings deep expertise in injectables, dry powder systems, liquids, lyophilization, and regulated market compliance. He has played a key role in setting up and scaling cGMP-compliant facilities aligned with global regulatory standards.
In his current role, Santosh focuses on operational excellence, process optimization, and cost-efficient manufacturing while fostering a strong quality and safety culture.
Collaborating with cross-functional teams to maintain consistent product quality, productivity, and timely supply to customers.
Ashwin John
Director, Planning & Projects
Ashwin John is the Director of Planning & Projects at BSL, with over a decade of experience within the Group. He specializes in planning, project management, strategic operations, and end-to-end R&D-to-commercialization execution.
Ashwin has successfully led major product launches, S&OP transformation initiatives, site transfers, and product lifecycle management. He is recognized for driving cross-functional collaboration, operational excellence, and seamless execution across complex pharmaceutical projects.
Krishnarao Shirsath
AVP, Head of Research & Development
Mr. Krishnarao Shirsath serves as Senior General Manager – Research & Development at BSL, bringing over 30 years of experience across pharmaceutical R&D, including API development (sterile and non-sterile), formulations, regulatory strategy, and global commercialization.
He has strong expertise in building high-performing R&D teams and delivering complex, first-to-market generic products in regulated markets, with dual specialization in Carbapenem API and sterile injectable development.
His career includes key innovations, patents, and publications, along with successful execution of three FTF molecules in cholesterol-lowering and antiviral segments. He also led the development and ANDA filing of Meropenem 2g Injection, securing the world’s first generic approval.
He combines scientific depth and regulatory expertise to accelerate development and build sustainable product pipelines.
Shivaji Salgaonkar
AVP, Head of Site Quality
Mr. Shivaji Salgaonkar serves as Senior General Manager – Site Quality Head, bringing over 20 years of experience in pharmaceutical quality, with a strong focus on sterile injectables.
He leads site-wide quality functions, ensuring robust compliance, system excellence, and data integrity aligned with global regulatory standards. He has extensive expertise in establishing and qualifying cGMP-compliant facilities, meeting requirements of agencies such as USFDA, EU, ANVISA, and other global regulators.
Throughout his career, he has driven digital quality transformation, laboratory automation, and continuous improvement initiatives, strengthening quality systems and operational reliability.
He is deeply focused on fostering a strong culture of quality ownership, accountability, and collaboration across teams, ensuring consistent delivery of safe, compliant, and high-quality products for global healthcare markets.
Shailendra Sharma
AVP, Human Resource
Mr. Shailendra Sharma brings over three decades of experience in Human Resource Management, Administration, and Legal Compliance within the pharmaceutical industry.
He has extensive expertise in Talent Management, Succession Planning, Competency Mapping, Performance Management, compensation benefits and Employee Lifecycle Management, SAP HR Module with a strong focus on strengthening organizational capability and driving people centric initiatives.
In his current role as a strategic business partner, he leads the implementation of, talent management frameworks, performance management, compensation benefits, employee retention strategy and employee engagement initiatives, enhancing workforce effectiveness and operational excellence.
He continues to focus on fostering a growth oriented workplace culture, ensuring statutory and legal compliance, and aligning people strategies with business objectives to support sustainable organizational growth.
Ankit Gupta
Chief Executive Officer
Operated by BSL, our state-of-the-art facility in Vadodara, Gujarat, is a dedicated Carbapenem manufacturing site with capabilities spanning API to finished dosage forms.
Spread across a 66,000 sqm cGMP-compliant campus, the facility offers dedicated Dry Powder Injection (DDP) and Lyophilized manufacturing lines, providing the flexibility and scale to meet diverse global supply requirements.
With annual capacity of up to ~28 million DDP units and ~1.2 million Lyophilized units, we combine manufacturing scale with specialized Carbapenem expertise.
Our backward-integrated API capabilities strengthen supply chain resilience, enhance operational efficiency, and provide a distinctive advantage in Carbapenem injectable manufacturing.
Approved by leading global regulatory authorities, including US FDA, EU-GMP, MHRA and Health Canada, with additional approvals across LATAM and the Middle East, the site brings regulatory confidence, integrated capabilities, and reliable supply to partners across the US, EU, and global markets. These regulatory approvals apply to our Finished Dose Formulation (FDF) facility, not the API facility.
From API to finished dose. From India to the world.
At Brooks, quality is built into every stage of our Carbapenem manufacturing, from raw material qualification to the final release of every vial. Our operations run under strict GMP, with validated processes, rigorous in-process controls, and comprehensive testing, so every batch consistently meets its specifications.
Our manufacturing, quality and regulatory teams work together to keep improving our processes, supported by strong data integrity and full traceability.
Our facility is approved by the US FDA, EU-GMP, MHRA, Health Canada, ANVISA, INVIMA and WHO, reflecting our readiness to serve the world's most regulated markets.
BSL leverages advanced, closed-system technology for the manufacturing of sterile Active Pharmaceutical Ingredients (APIs), supporting robust contamination control and consistent product quality. Our formulation capabilities include dry powder and lyophilized products manufactured using ALUS filling lines integrated with Restricted Access Barrier Systems (RABS). These advanced technologies enable controlled, high-quality injectable manufacturing while maintaining stringent standards of sterility, safety, and process reliability.
The lab comprises dedicated sterility and microbiological testing areas with restricted access and advanced systems to ensure reliable, accurate, and compliant microbiological testing.
Equipped with advanced analytical instruments for comprehensive on-site physico-chemical testing and stability studies.
Advanced pre-treatment system by Hydropure, India, with 9,000 L/hr capacity, featuring chlorination, filtration, softening, RO, and hot-water sanitization, compliant with quality standards.
High-capacity, advanced water system utilized for reliable and consistent PW generation, in compliance with USP, Pharm. Eur., and other relevant regulatory standards.
Advanced pure steam generation system with routine sampling and testing, in compliance with USP, Pharm. Eur., and other relevant regulatory standards.
Advanced water system utilized for WFI generation, with routine sampling and testing, in compliance with USP, Pharm. Eur., and other relevant regulatory standards.
